Trial Profile
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Ejection Fraction (AWAKE-HF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms AWAKE-HF
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 01 Dec 2021 Results assessing the effect of treatment with sacubitril/valsartan on sleep-related endpoints, published in the Journal of Cardiac Failure.
- 26 Sep 2020 Results published in the American Journal of Cardiovascular Drugs.
- 18 Mar 2019 Primary endpoint has not been met. (Ratio of Mean Activity Counts Collected During the Most Active 30 Minutes of the Subjects Day Between Week 8 and Baseline)